HRP20190896T1 - Inhibitori sintaze aldosterona - Google Patents

Inhibitori sintaze aldosterona Download PDF

Info

Publication number
HRP20190896T1
HRP20190896T1 HRP20190896TT HRP20190896T HRP20190896T1 HR P20190896 T1 HRP20190896 T1 HR P20190896T1 HR P20190896T T HRP20190896T T HR P20190896TT HR P20190896 T HRP20190896 T HR P20190896T HR P20190896 T1 HRP20190896 T1 HR P20190896T1
Authority
HR
Croatia
Prior art keywords
3alkyl
optionally substituted
heterocyclyl
compound according
following
Prior art date
Application number
HRP20190896TT
Other languages
English (en)
Croatian (hr)
Inventor
Keith R. Hornberger
Kenneth Michael MEYERS
Peter Allen Nemoto
Simon Surprenant
Hui Yu
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190896(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20190896T1 publication Critical patent/HRP20190896T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/54Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20190896TT 2014-10-15 2015-10-14 Inhibitori sintaze aldosterona HRP20190896T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
EP15785014.0A EP3207039B1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
HRP20190896T1 true HRP20190896T1 (hr) 2019-07-12

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190896TT HRP20190896T1 (hr) 2014-10-15 2015-10-14 Inhibitori sintaze aldosterona

Country Status (33)

Country Link
US (1) US9745289B2 (OSRAM)
EP (1) EP3207039B1 (OSRAM)
JP (1) JP6279812B2 (OSRAM)
KR (1) KR102441634B1 (OSRAM)
CN (1) CN107108587B (OSRAM)
AP (1) AP2017009829A0 (OSRAM)
AR (1) AR102266A1 (OSRAM)
AU (1) AU2015333611B2 (OSRAM)
CA (1) CA2964754C (OSRAM)
CL (1) CL2017000827A1 (OSRAM)
CO (1) CO2017003305A2 (OSRAM)
CY (1) CY1121650T1 (OSRAM)
DK (1) DK3207039T3 (OSRAM)
EA (1) EA031766B1 (OSRAM)
ES (1) ES2724555T3 (OSRAM)
HR (1) HRP20190896T1 (OSRAM)
HU (1) HUE043783T2 (OSRAM)
IL (1) IL251200B (OSRAM)
LT (1) LT3207039T (OSRAM)
ME (1) ME03381B (OSRAM)
MX (1) MX369025B (OSRAM)
NZ (1) NZ729688A (OSRAM)
PE (1) PE20170696A1 (OSRAM)
PH (1) PH12017500595B1 (OSRAM)
PL (1) PL3207039T3 (OSRAM)
PT (1) PT3207039T (OSRAM)
RS (1) RS58651B1 (OSRAM)
SG (1) SG11201701850UA (OSRAM)
SI (1) SI3207039T1 (OSRAM)
TR (1) TR201907755T4 (OSRAM)
TW (1) TWI731842B (OSRAM)
UA (1) UA118717C2 (OSRAM)
WO (1) WO2016061161A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CA3055292A1 (en) * 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
KR20240122521A (ko) 2021-12-14 2024-08-12 베링거 인겔하임 인터내셔날 게엠베하 만성 신장 질환 치료용 알도스테론 신타아제 억제제
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026688A (en) * 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
MY184008A (en) * 2009-05-15 2021-03-17 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
MY178867A (en) * 2011-11-30 2020-10-21 Hoffmann La Roche New bicyclic dihydroisoquinoline-1-one derivatives
JP6496246B2 (ja) * 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
RU2015140066A (ru) * 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
MX368093B (es) * 2014-07-24 2019-09-19 Boehringer Ingelheim Int Inhibidores de aldosterona sintasa.

Also Published As

Publication number Publication date
EA031766B1 (ru) 2019-02-28
EP3207039A1 (en) 2017-08-23
TWI731842B (zh) 2021-07-01
MX369025B (es) 2019-10-25
US9745289B2 (en) 2017-08-29
AR102266A1 (es) 2017-02-15
KR20170066651A (ko) 2017-06-14
TR201907755T4 (tr) 2019-06-21
NZ729688A (en) 2020-05-29
CO2017003305A2 (es) 2017-07-19
CA2964754C (en) 2023-01-24
PH12017500595B1 (en) 2020-11-25
WO2016061161A1 (en) 2016-04-21
MX2017004852A (es) 2017-06-22
PE20170696A1 (es) 2017-06-07
CA2964754A1 (en) 2016-04-21
KR102441634B1 (ko) 2022-09-13
RS58651B1 (sr) 2019-05-31
AP2017009829A0 (en) 2017-03-31
US20160108026A1 (en) 2016-04-21
AU2015333611A1 (en) 2017-03-23
CN107108587B (zh) 2020-05-22
HUE043783T2 (hu) 2019-09-30
JP6279812B2 (ja) 2018-02-14
SI3207039T1 (sl) 2019-05-31
IL251200A0 (en) 2017-05-29
TW201629048A (zh) 2016-08-16
PH12017500595A1 (en) 2017-08-30
CL2017000827A1 (es) 2017-11-03
AU2015333611B2 (en) 2020-02-06
CN107108587A (zh) 2017-08-29
JP2017531016A (ja) 2017-10-19
EP3207039B1 (en) 2019-03-06
CY1121650T1 (el) 2020-07-31
UA118717C2 (uk) 2019-02-25
PT3207039T (pt) 2019-06-04
ME03381B (me) 2020-01-20
PL3207039T3 (pl) 2019-08-30
IL251200B (en) 2019-05-30
BR112017005859A2 (pt) 2017-12-26
EA201790830A1 (ru) 2017-09-29
ES2724555T3 (es) 2019-09-12
DK3207039T3 (en) 2019-04-23
LT3207039T (lt) 2019-05-10
SG11201701850UA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
HRP20190896T1 (hr) Inhibitori sintaze aldosterona
CO2017011093A2 (es) Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen
PE20220143A1 (es) Agonistas de glp-1r y usos de los mismos
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
AR109348A1 (es) Sulfonilureas y compuestos relacionados y sus usos
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR112264A1 (es) Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas
AR091194A1 (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
HRP20180444T1 (hr) 9-aminometil-supstituirani tetraciklinski spojevi
JP2016530338A5 (OSRAM)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
RU2019114600A (ru) Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора
HRP20170403T1 (hr) SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
PE20161443A1 (es) Compuestos
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
AR081369A1 (es) Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen
PE20220253A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR094300A1 (es) Derivados de quinolonas
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
HRP20210038T1 (hr) Pirolopirimidini za uporabu u infekciji virusom gripe
JP2018522033A5 (OSRAM)
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma